5,568 Shares in Nutex Health Inc. $NUTX Acquired by Quantbot Technologies LP

Quantbot Technologies LP acquired a new stake in Nutex Health Inc. (NASDAQ:NUTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,568 shares of the company’s stock, valued at approximately $575,000. Quantbot Technologies LP owned about 0.10% of Nutex Health as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of NUTX. Topline Capital Management LLC lifted its stake in shares of Nutex Health by 72.0% in the 2nd quarter. Topline Capital Management LLC now owns 309,131 shares of the company’s stock valued at $38,484,000 after purchasing an additional 129,418 shares during the period. Vanguard Group Inc. grew its stake in shares of Nutex Health by 12.7% during the third quarter. Vanguard Group Inc. now owns 214,954 shares of the company’s stock worth $22,209,000 after purchasing an additional 24,275 shares during the period. American Century Companies Inc. increased its holdings in Nutex Health by 39.9% in the second quarter. American Century Companies Inc. now owns 104,063 shares of the company’s stock valued at $12,955,000 after purchasing an additional 29,704 shares during the last quarter. Marshall Wace LLP lifted its stake in Nutex Health by 333.4% in the second quarter. Marshall Wace LLP now owns 94,548 shares of the company’s stock valued at $11,770,000 after buying an additional 72,734 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Nutex Health by 116.8% in the second quarter. Geode Capital Management LLC now owns 78,859 shares of the company’s stock valued at $9,819,000 after buying an additional 42,484 shares during the period. Institutional investors and hedge funds own 5.32% of the company’s stock.

Nutex Health Stock Performance

Shares of NUTX opened at $90.28 on Monday. The firm’s 50 day moving average price is $136.67 and its two-hundred day moving average price is $124.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.39 and a current ratio of 3.41. Nutex Health Inc. has a twelve month low of $40.67 and a twelve month high of $193.07. The firm has a market cap of $629.25 million, a P/E ratio of 10.05 and a beta of 0.04.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings data on Thursday, March 5th. The company reported $1.61 EPS for the quarter, missing the consensus estimate of $5.56 by ($3.95). The company had revenue of $151.68 million during the quarter, compared to the consensus estimate of $258.82 million. Nutex Health had a net margin of 7.34% and a return on equity of 17.67%.

Key Nutex Health News

Here are the key news stories impacting Nutex Health this week:

• Positive Sentiment: Nutex reported strong full‑year 2025 results (revenue +82% y/y to $875.3M; net income and EPS up; adjusted EBITDA +152.6%) and announced a second stock repurchase program — news that can support the stock over time by reducing share count and signaling management confidence. NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
• Positive Sentiment: Analyst/coverage pieces are discussing valuation upside given earnings growth and the buyback, which may attract long‑term investors focused on fundamentals. Assessing Nutex Health (NUTX) Valuation After Earnings Growth And New Share Buyback Program
• Neutral Sentiment: Corporate press releases and financial filings provide the detailed numbers and management commentary — useful for investors doing due diligence but unlikely to move the market on their own. Company Press Release / Financial Report
• Negative Sentiment: Nutex’s most recent quarterly report missed expectations sharply (EPS $1.61 vs. $5.56 est.; revenue $151.7M vs. $258.8M), a short‑term catalyst for selling as it signals volatility in recent revenue drivers. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple law firms (Block & Leviton, Kuehn Law and others) have launched investigations or encouraged shareholders to contact them over potential securities fraud and fiduciary‑duty claims tied to disclosure of revenue recognition and internal controls — a major overhang that raises litigation risk, potential settlements, and reputational damage. Block & Leviton Investigation Notice
• Negative Sentiment: Additional press items detail similar shareholder litigation allegations about HaloMD-related revenue recognition, internal control weaknesses, and stock‑based compensation treatment — issues that could lead to restatements or future liabilities. Kuehn Law Notice
• Negative Sentiment: Local/regional reporting highlights investor outreach from law firms, amplifying negative headlines and short‑term selling pressure. GazetteXtra: Investor Advisory

Wall Street Analyst Weigh In

NUTX has been the subject of a number of recent analyst reports. Wall Street Zen cut Nutex Health from a “strong-buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of Nutex Health in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Nutex Health has an average rating of “Moderate Buy” and a consensus target price of $252.50.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.